Intellia Therapeutics (NTLA) Non-Current Assets (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Non-Current Assets of $292.3 million for Q1 2026, down 32.76% year-over-year from $434.8 million in Q1 2025, and down 7.02% quarter-over-quarter from $314.4 million in Q4 2025.
Intellia Therapeutics (NTLA) Non-Current Assets (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Non-Current Assets for 12 consecutive years, with $292.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 32.76% year-over-year to $292.3 million; the TTM figure through Mar 2026 stood at $1.4 billion (down 28.13% YoY), while the FY2025 annual figure was $314.4 million, down 42.95% from the prior year.
- Non-Current Assets retreated to $292.3 million in Q1 2026 per NTLA's latest filing, from $314.4 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $551.2 million in Q4 2024 and bottomed at $215.0 million in Q2 2022.
- Historically, Non-Current Assets has averaged $363.1 million across 5 years, with a median of $349.9 million in 2023.
- On a YoY basis, Non-Current Assets climbed as much as 182.73% in 2022 and fell as far as 56.65% in 2022.
- Intellia Therapeutics' Non-Current Assets stood at $303.3 million in 2022, then fell by 0.22% to $302.6 million in 2023, then surged by 82.11% to $551.2 million in 2024, then tumbled by 42.95% to $314.4 million in 2025, then declined by 7.02% to $292.3 million in 2026.
- Business Quant data shows NTLA's Non-Current Assets at $292.3 million in Q1 2026, $314.4 million in Q4 2025, and $343.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 329.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 329.33 Mn |
| Mar 31, 2026 | 292.33 Mn |
| Dec 31, 2025 | 314.42 Mn |
| Sep 30, 2025 | 343.33 Mn |
| Jun 30, 2025 | 402.95 Mn |
| Mar 31, 2025 | 434.77 Mn |
| Dec 31, 2024 | 551.15 Mn |
| Sep 30, 2024 | 462.45 Mn |
| Jun 30, 2024 | 434.33 Mn |
| Mar 31, 2024 | 375.55 Mn |
| Dec 31, 2023 | 302.65 Mn |
| Sep 30, 2023 | 349.86 Mn |
| Jun 30, 2023 | 383.63 Mn |
| Mar 31, 2023 | 454.22 Mn |
| Dec 31, 2022 | 303.32 Mn |
| Sep 30, 2022 | 225.51 Mn |
| Jun 30, 2022 | 214.99 Mn |
| Mar 31, 2022 | 327.42 Mn |
| Dec 31, 2021 | 525.16 Mn |
| Sep 30, 2021 | 520.19 Mn |